Epiplakin expression in non-melanoma skin cancer: associations with epithelial-mesenchymal transition markers and tumor invasion
Anais Brasileiros de Dermatologia · 2026-05 · 101 (3) · 501350
DOI: 10.1016/j.abd.2026.501350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anais Brasileiros de Dermatologia, 2026-05. Verfasst von Damla Gül Fındık und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histology and Embryology, Faculty of Medicine, Balıkesir University, Balıkesir, Turkey. Electronic address: damla.findik@balikesir.edu.…. Hauptthemen laut MEDLINE: Basal Cell Carcinoma, Non-Melanoma Skin Neoplasms, Skin Neoplasms. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Epiplakin is a member of the plakin family of proteins involved in cytoskeletal organization, yet its role in skin cancers remains poorly understood. This study aimed to evaluate epiplakin expression in cutaneous skin lesions and to investigate its associa-tion with epithelial-mesenchymal transition markers and tumor progression.
Methods
The authors retrospectively analyzed skin specimens from squamous cell carcino-mas, basal cell carcinomas, and benign intradermal nevi collected between 2021 and 2025. Histopathological features were assessed, and immunohistochemical analysis of Epiplakin, E-cadherin, and N-cadherin was performed. Epiplakin expression was quantified and correlated with cadherin levels and Breslow thickness. Plakin family protein-protein interaction networks were analyzed using KEGG pathway and GO functional enrichment.
Results
Protein-protein interaction network analysis demonstrated that plakin family mem-bers are associated with multiple cancer-related pathways, with a prominent enrichment in regulating cell proliferation. Epiplakin expression was significantly higher in squamous cell car-cinomas (389.94 ± 70.56) compared with basal cell carcinomas (70.39 ± 15.32) and intradermal nevi, while basal cell carcinomas showed a significant decrease compared with normal skin (p < 0.05). In non-melanoma skin cancers, epiplakin expression demonstrated a strong positive correlation with E-cadherin (r = 0.565, p < 0.001) and a weak positive correlation with N-cadherin (r = 0.329, p < 0.05). No significant correlation was observed with Breslow thickness (p > 0.05). Study limitations: Retrospective design and the absence of high-grade squamous cell carcinoma cases in the study population.
Conclusions
This is the first study to assess epiplakin expression among epithelial cutaneous cancers. Epiplakin appears to be associated with epithelial-mesenchymal transition and early tumor progression, and its differential expression pattern may provide diagnostic utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Histology and Embryology, Faculty of Medicine, Balıkesir University, Balıkesir, Turkey. Electronic address: damla.findik@balikesir.edu.tr.
- Department of Pathology, Faculty of Medicine, Bilecik Şeyh Edebali University, Bilecik, Turkey.
Zitieren
APA
Fındık, D. G., & Türelik, Ö. (2026). Epiplakin expression in non-melanoma skin cancer: associations with epithelial-mesenchymal transition markers and tumor invasion. Anais Brasileiros de Dermatologia, 101(3), 501350. https://doi.org/10.1016/j.abd.2026.501350
Vancouver
Fındık DG, Türelik Ö. Epiplakin expression in non-melanoma skin cancer: associations with epithelial-mesenchymal transition markers and tumor invasion. Anais Brasileiros de Dermatologia. 2026;101(3):501350. doi:10.1016/j.abd.2026.501350
BibTeX
@article{Fndk2026,
author = {Fındık, Damla Gül and Türelik, Özlem},
title = {Epiplakin expression in non-melanoma skin cancer: associations with epithelial-mesenchymal transition markers and tumor invasion},
journal = {Anais Brasileiros de Dermatologia},
year = {2026},
volume = {101},
number = {3},
pages = {501350},
doi = {10.1016/j.abd.2026.501350}
}
EUVIMED